Revlimid 10mg

Antitumor remedy, immunomodulator. Revlimid 10mg is the representative of a new class of immunomodulators (IMiDsSM), which has both immunomodulatory and anti-angiogenic properties.

Clinical efficacy and safety of Revlimid was confirmed by the results of two multicenter random phases III trials in which patients with multiple myeloma received Revlimid together with dexamethasone or only one dexamethasone as 2nd line therapy. For all the efficacy criteria, including the percentage of complete and partial responses, combined therapy with Revlimid and dexamethasone was superior to monotherapy with dexamethasone.

Dosage

Revlimid 10mg is intended only for oral administration.

Capsules of Revlimid 10mg cannot be broken or chewed. It is recommended to take the remedy every day at the same time before or after eating, squeezed with water.

The recommended initial dose of Revlimid is 25 mg 1 time / day in 1-21 days of repeated 28-day cycles.

The remedy is contraindicated in pregnancy and lactation (breastfeeding).

Women of reproductive age should be treated with effective methods of contraception during the treatment with Revlimid 10mg. The using of Lenalidomide should be discontinued if a woman is diagnosed with pregnancy.

It is not known whether Lenalidomide penetrates breast milk. In this regard, during the treatment with Lenalidomide, breastfeeding should be discontinued.

Side effects

In patients receiving Revlimid / dexamethasone, the following adverse reactions were most common: neutropenia, muscle weakness, asthenia, constipation, muscle cramps, thrombocytopenia, anemia, diarrhea, rash.

The most severe adverse reactions: venous thromboembolism (deep vein thrombosis, pulmonary embolism, pulmonary embolism), grade 4 neutropenia.

Interaction with other remedies:

Mutual influence on the metabolism of Lenalidomide and other remedies is unlikely. It is undesirable to simultaneously use Revlimid with Digoxin due to an increase in its plasma concentration. Dexamethasone, which is an obligatory component of the treatment regimen with Revlimid, can reduce the effectiveness of oral contraceptives.
There was no mutual influence on the pharmacokinetic parameters of Lenalidomide and Warfarin.